

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances  
NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent  
equivalents from China  
NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced  
NEWS 29 APR 03 CAS coverage of exemplified prophetic substances  
enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:51:07 ON 06 APR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:51:15 ON 06 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2  
DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10551737 elected April 6.str



```

chain nodes :
10 11 12 18 19 20 22
ring nodes :
1 2 3 4 5 6 13 14 15 16 17
chain bonds :
3-11 4-10 10-22 11-12 15-18 16-22 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-17 14-15 15-16 16-17
exact/norm bonds :
3-11 4-10 10-22 11-12 15-16 16-17 16-22 18-19 18-20
exact bonds :
13-14 13-17 14-15 15-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 13 :

```

G1:O,S

G2:Cb,Cy,Hy

G3:C,O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 10:CLASS 11:CLASS 12:CLASS
13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 22:CLASS

```

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.



DOCUMENT NUMBER: 145:432223  
 TITLE: Method of treating schizophrenia prodrome  
 INVENTOR(S): Woods, Scott W.  
 PATENT ASSIGNEE(S): Yale University, USA  
 SOURCE: PCT Int. Appl., 64pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110724	A2	20061019	WO 2006-US13444	20060411
WO 2006110724	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006235400	A1	20061019	AU 2006-235400	20060411
CA 2602626	A1	20061019	CA 2006-2602626	20060411
EP 1871165	A2	20080102	EP 2006-740849	20060411
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008535864	T	20080904	JP 2008-505637	20060411
PRIORITY APPLN. INFO.:			US 2005-670600P	P 20050411
			WO 2006-US13444	W 20060411

OTHER SOURCE(S): MARPAT 145:432223


AB The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixts. thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.

IT 791642-83-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (method of treating schizophrenia prodrome with NMDA glycine agonist and glycine transporter-1 inhibitor)

RN 791642-83-6 CAPLUS


CN L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:625349 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 145:224321  
 TITLE: The synthesis and SAR of  
 2-arylsulfanylmethyl-1-oxyalkylamino acids as GlyT-1  
 inhibitors  
 AUTHOR(S): Smith, Garrick; Mikkelsen, Gitte; Eskildsen, Jorgen;  
 Bundgaard, Christoffer  
 CORPORATE SOURCE: Medicinal Chemistry Research, H. Lundbeck A/S, Valby,  
 DK 2500, Den.  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),  
 16(15), 3981-3984  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 145:224321  
 GI



AB Elevation of glycine levels by inhibition of the glycine transporter-1 (GlyT-1) and activation of the NMDA receptor is a potential strategy for the treatment of schizophrenia. A novel series of 2-arylsulfanylmethyl-1-oxyalkyl amino acids have been identified. The most prominent member of this series (I) is a potent GlyT-1 inhibitor (IC<sub>50</sub> = 59 nM). In vitro and in vivo assessment of CNS exposure indicates this compound is a likely substrate for active efflux transporters.


IT 791644-20-7P 791644-21-8P  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1 inhibitors)

RN 791644-20-7 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-21-8 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 791642-87-0P 791644-17-2P 791644-18-3P  
794510-03-5P 905815-62-5P 905815-63-6P  
905815-64-7P 905815-65-8P 905815-66-9P  
905815-67-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1 inhibitors)

RN 791642-87-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-17-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-18-3 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 794510-03-5 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 905815-62-5 CAPLUS

CN D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-63-6 CAPLUS

CN L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-64-7 CAPLUS

CN L-Proline, 1-[2-[4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-65-8 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(3-thienyl)phenoxy]ethyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 905815-66-9 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-67-0 CAPLUS


CN L-Proline, 1-[2-[[4'-chloro-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 791642-79-0P 791644-01-4P 905816-02-6P  
905816-03-7P 905816-06-0P 905816-07-1P  
905816-08-2P 905816-09-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and SAR of arylsulfanylphenoxyalkylamino acids as GlyT-1  
inhibitors)  
RN 791642-79-0 CAPLUS  
CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,  
1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 791644-01-4 CAPLUS  
CN L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,  
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-02-6 CAPLUS

CN D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-03-7 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-06-0 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-07-1 CAPLUS

CN L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-08-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-09-3 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965214 CAPLUS Full-text

DOCUMENT NUMBER: 141:411217

TITLE: A preparation of oxyphenyl and sulfanyphenyl derivatives of amino acids, useful as glycine transporter inhibitors

INVENTOR(S): Smith, Garrick Paul; Mikkelsen, Gitte; Andersen, Kim; Greve, Daniel Rodriguez; Eskildsen, Joergen

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096761	A1	20041111	WO 2004-DK290	20040427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004233942	A1	20041111	AU 2004-233942	20040427
CA 2523585	A1	20041111	CA 2004-2523585	20040427
EP 1622868	A1	20060208	EP 2004-729612	20040427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009739	A	20060509	BR 2004-9739	20040427
JP 2006524642	T	20061102	JP 2006-504368	20040427
MX 2005011198	A	20051214	MX 2005-11198	20051018
IN 2005CN02812	A	20070525	IN 2005-CN2812	20051031
NO 2005005632	A	20051129	NO 2005-5632	20051129
US 20060235003	A1	20061019	US 2006-551737	20060606
PRIORITY APPLN. INFO.:			DK 2003-649	A 20030430
			US 2003-466755P	P 20030430

OTHER SOURCE(S):  
GI

MARPAT 141:411217



AB The invention relates to a preparation of aromatic oxyphenyl and aromatic sulfanylphenyl derivs. of formula I [wherein: X is O, S, or CH<sub>2</sub>, etc.; Y is O or S; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are independently selected from H, halogen, CN, NO<sub>2</sub>, or alk(en/yn)yl, etc.; R<sub>5</sub> is (un)substituted aryl or monocyclic heteroaryl; R<sub>6</sub> is H, alk(en/yn)yl, cycloalk(en)yl, or alk(en/yn)ylsulfanyl, etc.; R<sub>7</sub> and R<sub>8</sub> are independently selected from H, alk(en/yn)yl, or cycloalk(en)yl; R<sub>9</sub> and R<sub>11</sub> are independently selected from H, alk(en/yn)yl, hydroxyalk(en/yn)yl, or alk(en/yn)ylsulfanyl, etc.; R<sub>10</sub> is H, alk(en/yn)yl, aryl, or arylalk(en/yn)yl, etc.; R<sub>6</sub> and R<sub>8</sub> together with the nitrogen may form 3-7 membered heterocyclic ring], useful as glycine transporter inhibitors (IC<sub>50</sub> < 10000 nM). The compds. of formula I are useful for the treatment of diseases such as schizophrenia, including both the pos. and the neg. symptoms of schizophrenia. For instance, pyrrolidinecarboxylic acid derivative II was prepared via etherification of 2-(3-fluorophenylsulfanyl)phenol by (hydroxyethyl)pyrrolidinecarboxylate derivative III.

IT 791642-79-0P, (S)-1-[2-[4-Bromo-2-(3-fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid tert-butyl ester


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of oxyphenyl and sulfanylphenyl derivs. of amino acids, useful as glycine transporter inhibitors)

RN 791642-79-0 CAPLUS

CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 791642-81-4P, (S)-1-[2-[2-(4-Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-83-6P, (S)-1-[2-[2-(4-tert-Butylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-84-7P, (S)-1-[2-[2-(4-Trifluoromethylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-85-8P, (S)-1-[2-[2-(3-Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-86-9P, (S)-1-[2-[2-(4-Chlorophenylsulfanyl)-phenoxy]-ethyl]pyrrolidine-2-carboxylic acid 791642-87-0P, (S)-1-[2-[2-(3-Chlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid 791642-88-1P, (S)-1-[2-[2-(3,4-Dichlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-90-5P, (S)-1-[2-[2-(3-Chloro-4-fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-91-6P, (S)-1-[2-[2-(3-Chlorophenoxy)phenoxy]ethyl]pyrrolidine-2-carboxylic acid  
 791642-92-7P 791642-93-8P 791642-94-9P  
 791642-95-0P 791642-97-2P 791642-98-3P  
 791642-99-4P 791643-00-0P 791643-01-1P  
 791643-85-1P 791643-88-4P 791643-90-8P  
 791643-91-9P 791643-92-0P 791643-94-2P  
 791643-95-3P 791643-97-5P 791643-99-7P  
 791644-00-3P 791644-02-5P 791644-04-7P  
 791644-06-9P 791644-08-1P 791644-09-2P  
 791644-15-0P 791644-17-2P 791644-18-3P  
 791644-19-4P 791644-20-7P 791644-21-8P  
 791644-22-9P 791644-23-0P 791644-24-1P  
 791644-25-2P 791644-26-3P 791644-27-4P  
 791644-28-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of oxyphenyl and sulfanylphenyl derivs. of amino acids, useful as glycine transporter inhibitors)

RN 791642-81-4 CAPLUS

CN L-Proline, 1-[2-[2-[(4-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 791642-83-6 CAPLUS

CN L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-84-7 CAPLUS

CN L-Proline, 1-[2-[2-[[4-(trifluoromethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-85-8 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-86-9 CAPLUS

CN L-Proline, 1-[2-[2-[(4-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-87-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-88-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3,4-dichlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-90-5 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chloro-4-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-91-6 CAPLUS

CN L-Proline, 1-[2-[2-(3-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-92-7 CAPLUS

CN L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-93-8 CAPLUS

CN L-Proline, 1-[2-[2-(4-methoxyphenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-94-9 CAPLUS

CN L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-95-0 CAPLUS

CN L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-97-2 CAPLUS

CN L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-98-3 CAPLUS

CN L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-99-4 CAPLUS

CN L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-00-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-01-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-85-1 CAPLUS

CN L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]-, hydrochloride  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-88-4 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-90-8 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-91-9 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-92-0 CAPLUS

CN L-Proline, 1-[2-[4-cyano-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791643-94-2 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 791643-95-3 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-97-5 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-99-7 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 791644-00-3 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-5-(3-thienyl)phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

OC(=O)[C@H]1CCCN1CCOC2=CC=C(C=C2Sc3ccc(F)cc3)c4ccccc4S5=CC=CC=C5

● HCl

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(5-pyrimidinyl)phenoxy]ethyl]-  
, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-06-9 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-08-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-09-2 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-15-0 CAPLUS

CN L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-17-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-18-3 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-19-4 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-20-7 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 791644-21-8 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-22-9 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-23-0 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-24-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-5-(3-thienyl)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 791644-25-2 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(5-pyrimidinyl)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 791644-26-3 CAPLUS

CN L-Proline, 1-[2-[3-[3-(3-fluorophenyl)thio]-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-27-4 CAPLUS

CN L-Proline, 1-[2-[2-[3-(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-28-5 CAPLUS


CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



IT 791643-98-6 791644-01-4 791644-07-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant; preparation of oxyphenyl and sulfanylphenyl derivs. of amino  
acids, useful as glycine transporter inhibitors)  
RN 791643-98-6 CAPLUS  
CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,  
hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 791644-01-4 CAPLUS  
CN L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,  
1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 791644-07-0 CAPLUS  
 CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:666715 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 133:252449  
 TITLE: Quinazolines and other bicyclic heterocycles, pharmaceutical compositions containing these compounds as tyrosine kinase inhibitors, and processes for preparing them  
 INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Blech, Stefan; Jung, Birgit; Metz, Thomas; Solca, Flavio  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 153 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055141	A1	20000921	WO 2000-EP2228	20000314
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19911509	A1	20000921	DE 1999-19911509	19990315
CA 2368059	A1	20000921	CA 2000-2368059	20000314
EP 1163227	A1	20011219	EP 2000-909360	20000314
EP 1163227	B1	20050928		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

BR 2000009076	A	20011226	BR 2000-9076	20000314
TR 200102782	T2	20020422	TR 2001-2782	20000314
JP 2002539199	T	20021119	JP 2000-605571	20000314
JP 3754617	B2	20060315		
EE 200100484	A	20021216	EE 2001-484	20000314
EE 5034	B1	20080616		
HU 2002001832	A2	20021228	HU 2002-1832	20000314
HU 2002001832	A3	20030228		
NZ 514706	A	20031128	NZ 2000-514706	20000314
AU 772520	B2	20040429	AU 2000-31667	20000314
CN 1150171	C	20040519	CN 2000-805005	20000314
AT 305456	T	20051015	AT 2000-909360	20000314
ES 2250111	T3	20060416	ES 2000-909360	20000314
IL 144626	A	20070211	IL 2000-144626	20000314
TW 268924	B	20061221	TW 2000-89104508	20000426
IN 2001MN00956	A	20050304	IN 2001-MN956	20010809
MX 2001008324	A	20020311	MX 2001-8324	20010816
US 20020177601	A1	20021128	US 2001-938235	20010823
ZA 2001007185	A	20020621	ZA 2001-7185	20010830
BG 105893	A	20020531	BG 2001-105893	20010912
BG 65130	B1	20070330		
KR 749292	B1	20070814	KR 2001-711645	20010913
NO 2001004487	A	20010914	NO 2001-4487	20010914
HK 1043124	A1	20041203	HK 2002-104697	20020625
JP 2006077010	A	20060323	JP 2005-259571	20050907
US 20060063752	A1	20060323	US 2005-266920	20051104

PRIORITY APPLN. INFO.:


DE 1999-19911509	A	19990315
JP 2000-605571	A3	20000314
WO 2000-EP2228	W	20000314
US 2001-938235	A1	20010823

OTHER SOURCE(S): MARPAT 133:252449  
 GI



- AB The invention relates to bicyclic heterocyclic compds. I [R1 = H, alkyl; R2 = (un)substituted Ph, CH<sub>2</sub>Ph, or CH(Me)Ph; R3, R4 = H, F, Cl, OMe, or Me optionally substituted by OMe, NMe<sub>2</sub>, NEt<sub>2</sub>, pyrrolidino, piperidino, or morpholino; X = N or C(CN); A = O, NH, (un)substituted alkylene, O-alkylene, NH-alkylene, O-cycloalkylene, etc.; B = (un)substituted amine-containing sidechain, piperazino, alkyleneimino, morpholino, etc.; or AB = H, F, Cl, alkoxy, amino, etc.; C = groups similar to A; D = groups similar to B; with a variety of provisos] and their tautomers, stereoisomers, and salts, and particularly their physiol. acceptable salts with inorg. or organic acids or bases. The compds. have valuable pharmacol. properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, and are useful in treating diseases, particularly tumor diseases, and diseases of the lung and airways. Over 20 compds. were prepared, and over 200 are listed. For instance, alkylation of 4-(3-chloro-4-fluorophenylamino)-6-[3-(1-piperazinyl)propyloxy]-7-methoxyquinazoline (preparation given) by Me bromoacetate gave 51% title compound II. The latter compound inhibited EGF-dependent proliferation of F/L-HERc cells in vitro, with an IC<sub>50</sub> of 46 nM.
- IT 295330-27-7P, (R)-4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-[2-(methoxycarbonyl)pyrrolidin-1-yl]ethoxy]-7-cyclopentyloxyquinazoline  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of quinazoline derivs. and other bicyclic heterocycles as tyrosine kinase inhibitors)
- RN 295330-27-7 CAPLUS
- CN D-Proline, 1-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]oxy]ethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1973:64458 CAPLUS Full-text

DOCUMENT NUMBER: 78:64458

ORIGINAL REFERENCE NO.: 78:10181a,10184a

TITLE: Detection of alkali metal ions by optical rotatory dispersion. Sensitive test for sodium in the presence of lithium and potassium

AUTHOR(S): Wudl, Fred

CORPORATE SOURCE: Dep. Chem., State Univ. N. Y., Buffalo, NY, USA

SOURCE: Journal of the Chemical Society, Chemical

Communications (1972), (22), 1229-30

CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB The ORD curves of the chiral semicrown complexes (I, M = H, Li, Na, K) depend on the cation (M) and, as the interaction of I its strongest with Na, a spectropolarimetric determination of Na in the presence of Li and K is applicable.

IT 40418-12-0P

RL: PREP (Preparation)  
(preparation of)

RN 40418-12-0 CAPLUS

CN Proline, 1-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]phenoxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 08:52:06 ON 06 APR 2009